Skip to main content
. 2022 Feb 12;11(4):e024159. doi: 10.1161/JAHA.121.024159

Table 2.

Primary and Secondary Outcomes by CYP2C19 and Antiplatelet Therapy

Clinical outcome by CYP2C19‐P2Y12 inhibitor Event no.* Event rate (per 100 patient years) Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
Primary outcome
Major atherothrombotic events
LOF‐clopidogrel 71 34.4 Reference Reference
LOF‐alternative 51 17.1 0.50 (0.35–0.72) <0.001 0.56 (0.39–0.82) 0.002
Non‐LOF‐clopidogrel 197 19.9 Reference Reference
Non‐LOF‐alternative 34 18.1 0.91 (0.63–1.30) 0.591 1.08 (0.72–1.62) § 0.715
Secondary outcomes
Major atherothrombotic events at 90 d
LOF‐clopidogrel 40 52.5 Reference Reference
LOF‐alternative 20 18.9 0.37 (0.22–0.63) <0.001 0.40 (0.23–0.71) 0.002
Non‐LOF‐clopidogrel 104 30.8 Reference Reference
Non‐LOF‐alternative 18 26.1 0.84 (0.51–1.39) 0.502 1.09 (0.64–1.86) 0.752
Clinically significant bleeding events
LOF‐clopidogrel 15 7.1 Reference Reference
LOF‐alternative 25 7.9 1.13 (0.60–2.15) 0.705 1.15 (0.60–2.20) 0.685
Non‐LOF‐clopidogrel 69 6.8 Reference Reference
Non‐LOF‐alternative 15 7.4 1.10 (0.63–1.92) 0.745 1.30 (0.71–2.38) 0.397

GIB indicates gastrointestinal bleed; HR, hazard ratio; ICH, intracerebral brain hemorrhage; LOF, loss‐of function; and PCI, percutaneous coronary intervention.

*

Data are presented as the number of patients in each group who experienced the event over 12 months of follow‐up after the index PCI.

The event rate was calculated as the number of events per 100 patient‐years of follow‐up.

The hazard ratio was adjusted with stabilized inverse probability weights derived from exposure propensity scores.

§

The HR after adjusting for history of GIB or ICH: adjusted HR 1.08; 95% CI, 0.72–1.62; P=0.726.